APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Sitagliptin Metformin Extended Release Tablets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Sitagliptin Metformin Extended Release Tablets Market Outlook and Growth Opportunities 2026

Report ID 174035870427 December 2025190 pages

Choose your research edition.

Industry ResearchSitagliptin Metformin Extended Release Tablets Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Sitagliptin Metformin Extended Release Tablets Industry Growth and Trends Forecast to 203297 pages · $3,450 USDMarket StructureGlobal Sitagliptin Metformin Extended Release Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Sitagliptin Metformin Extended Release Tablets Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Sitagliptin Metformin Extended Release Tablets Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Sitagliptin Metformin Extended Release Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Sitagliptin Metformin Extended Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Sitagliptin Metformin Extended Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Sitagliptin Metformin Extended Release Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Sitagliptin Metformin Extended Release Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Sitagliptin Metformin Extended Release Tablets market include Chia Tai Tianqing Pharmaceutical Group, Jiangsu Xuantai Pharmaceutical Co., Ltd., Jiangsu Anbisheng Pharmaceutical Co., Ltd., Sandoz Pty Ltd, Merck & Co., Inc. and Abbott, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Sitagliptin Metformin Extended Release Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Sitagliptin Metformin Extended Release Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Sitagliptin Metformin Extended Release Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Sitagliptin Metformin Extended Release Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Sitagliptin Metformin Extended Release Tablets Segment by Company

Chia Tai Tianqing Pharmaceutical Group

Jiangsu Xuantai Pharmaceutical Co., Ltd.

Jiangsu Anbisheng Pharmaceutical Co., Ltd.

Sandoz Pty Ltd

Merck & Co., Inc.

Abbott

Sitagliptin Metformin Extended Release Tablets Segment by Type

Sitagliptin Phosphate 50mg (Calculated as C₁₆H₁₅F₆N₅O) and Metformin Hydrochloride 500mg

Sitagliptin Phosphate 100mg (Calculated as C16H15F6N5O) and Metformin Hydrochloride 1000mg

Sitagliptin Metformin Extended Release Tablets Segment by Application

Hospital

Clinic

Other

Sitagliptin Metformin Extended Release Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Sitagliptin Metformin Extended Release Tablets status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Sitagliptin Metformin Extended Release Tablets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Sitagliptin Metformin Extended Release Tablets significant trends, drivers, influence factors in global and regions.

6. To analyze Sitagliptin Metformin Extended Release Tablets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sitagliptin Metformin Extended Release Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Sitagliptin Metformin Extended Release Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sitagliptin Metformin Extended Release Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Sitagliptin Metformin Extended Release Tablets market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Sitagliptin Metformin Extended Release Tablets industry.

Chapter 3: Detailed analysis of Sitagliptin Metformin Extended Release Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Sitagliptin Metformin Extended Release Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Sitagliptin Metformin Extended Release Tablets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Sitagliptin Metformin Extended Release Tablets Industry Trends Table 2. Sitagliptin Metformin Extended Release Tablets Industry Drivers Table 3. Sitagliptin Metformin Extended Release Tablets Industry Opportunities and Challenges Table 4. Sitagliptin Metformin Extended Release Tablets Industry Restraints Table 5. Global Sitagliptin Metformin Extended Release Tablets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Sitagliptin Metformin Extended Release Tablets Revenue Share by Company (2021-2026) Table 7. Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share by Company (2021-2026) Table 9. Global Sitagliptin Metformin Extended Release Tablets Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Sitagliptin Metformin Extended Release Tablets Company Ranking, (2024-2026) & (USD Million) Table 11. Global Sitagliptin Metformin Extended Release Tablets Key Company Manufacturing Base & Headquarters Table 12. Global Sitagliptin Metformin Extended Release Tablets Company, Product Type & Application Table 13. Global Sitagliptin Metformin Extended Release Tablets Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Sitagliptin Metformin Extended Release Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Sitagliptin Phosphate 50mg (Calculated as C₁₆H₁₅F₆N₅O) and Metformin Hydrochloride 500mg Table 18. Significant Companies of Sitagliptin Phosphate 100mg (Calculated as C16H15F6N5O) and Metformin Hydrochloride 1000mg Table 19. Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share by Type (2021-2026) Table 23. Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share by Type (2027-2032) Table 24. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type (2021-2026) Table 28. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Other Table 32. Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Application (2021-2026) & (K Units) Table 34. Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Application (2027-2032) & (K Units) Table 35. Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share by Application (2021-2026) Table 36. Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share by Application (2027-2032) Table 37. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application (2021-2026) Table 41. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application (2027-2032) Table 42. Global Sitagliptin Metformin Extended Release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global Sitagliptin Metformin Extended Release Tablets Sales by Region (2021-2026) & (K Units) Table 44. Global Sitagliptin Metformin Extended Release Tablets Sales Market Share by Region (2021-2026) Table 45. Global Sitagliptin Metformin Extended Release Tablets Sales by Region (2027-2032) & (K Units) Table 46. Global Sitagliptin Metformin Extended Release Tablets Sales Market Share by Region (2027-2032) Table 47. Global Sitagliptin Metformin Extended Release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Region (2021-2026) Table 50. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Region (2027-2032) Table 52. Global Sitagliptin Metformin Extended Release Tablets Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global Sitagliptin Metformin Extended Release Tablets Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global Sitagliptin Metformin Extended Release Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Sitagliptin Metformin Extended Release Tablets Sales by Country (2021-2026) & (K Units) Table 57. Global Sitagliptin Metformin Extended Release Tablets Sales Market Share by Country (2021-2026) Table 58. Global Sitagliptin Metformin Extended Release Tablets Sales by Country (2027-2032) & (K Units) Table 59. Global Sitagliptin Metformin Extended Release Tablets Sales Market Share by Country (2027-2032) Table 60. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Sitagliptin Metformin Extended Release Tablets Sales Value Market Share by Country (2021-2026) Table 62. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Sitagliptin Metformin Extended Release Tablets Sales Value Market Share by Country (2027-2032) Table 64. Chia Tai Tianqing Pharmaceutical Group Company Information Table 65. Chia Tai Tianqing Pharmaceutical Group Business Overview Table 66. Chia Tai Tianqing Pharmaceutical Group Sitagliptin Metformin Extended Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Chia Tai Tianqing Pharmaceutical Group Sitagliptin Metformin Extended Release Tablets Product Portfolio Table 68. Chia Tai Tianqing Pharmaceutical Group Recent Development Table 69. Jiangsu Xuantai Pharmaceutical Co., Ltd. Company Information Table 70. Jiangsu Xuantai Pharmaceutical Co., Ltd. Business Overview Table 71. Jiangsu Xuantai Pharmaceutical Co., Ltd. Sitagliptin Metformin Extended Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Jiangsu Xuantai Pharmaceutical Co., Ltd. Sitagliptin Metformin Extended Release Tablets Product Portfolio Table 73. Jiangsu Xuantai Pharmaceutical Co., Ltd. Recent Development Table 74. Jiangsu Anbisheng Pharmaceutical Co., Ltd. Company Information Table 75. Jiangsu Anbisheng Pharmaceutical Co., Ltd. Business Overview Table 76. Jiangsu Anbisheng Pharmaceutical Co., Ltd. Sitagliptin Metformin Extended Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Jiangsu Anbisheng Pharmaceutical Co., Ltd. Sitagliptin Metformin Extended Release Tablets Product Portfolio Table 78. Jiangsu Anbisheng Pharmaceutical Co., Ltd. Recent Development Table 79. Sandoz Pty Ltd Company Information Table 80. Sandoz Pty Ltd Business Overview Table 81. Sandoz Pty Ltd Sitagliptin Metformin Extended Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Sandoz Pty Ltd Sitagliptin Metformin Extended Release Tablets Product Portfolio Table 83. Sandoz Pty Ltd Recent Development Table 84. Merck & Co., Inc. Company Information Table 85. Merck & Co., Inc. Business Overview Table 86. Merck & Co., Inc. Sitagliptin Metformin Extended Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Merck & Co., Inc. Sitagliptin Metformin Extended Release Tablets Product Portfolio Table 88. Merck & Co., Inc. Recent Development Table 89. Abbott Company Information Table 90. Abbott Business Overview Table 91. Abbott Sitagliptin Metformin Extended Release Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Abbott Sitagliptin Metformin Extended Release Tablets Product Portfolio Table 93. Abbott Recent Development Table 94. Key Raw Materials Table 95. Raw Materials Key Suppliers Table 96. Sitagliptin Metformin Extended Release Tablets Distributors List Table 97. Sitagliptin Metformin Extended Release Tablets Customers List Table 98. Research Programs/Design for This Report Table 99. Authors List of This Report Table 100. Secondary Sources Table 101. Primary Sources List of Figures Figure 1. Sitagliptin Metformin Extended Release Tablets Product Image Figure 2. Global Sitagliptin Metformin Extended Release Tablets Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 4. Global Sitagliptin Metformin Extended Release Tablets Sales (2021-2032) & (K Units) Figure 5. Global Sitagliptin Metformin Extended Release Tablets Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Sitagliptin Metformin Extended Release Tablets Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Sitagliptin Phosphate 50mg (Calculated as C₁₆H₁₅F₆N₅O) and Metformin Hydrochloride 500mg Image Figure 10. Sitagliptin Phosphate 100mg (Calculated as C16H15F6N5O) and Metformin Hydrochloride 1000mg Image Figure 11. Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share by Type (2021-2032) Figure 14. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Other Image Figure 20. Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share by Application (2021-2032) Figure 23. Global Sitagliptin Metformin Extended Release Tablets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application (2021-2032) Figure 26. Global Sitagliptin Metformin Extended Release Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global Sitagliptin Metformin Extended Release Tablets Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Sitagliptin Metformin Extended Release Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 31. North America Sitagliptin Metformin Extended Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Sitagliptin Metformin Extended Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Sitagliptin Metformin Extended Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 37. South America Sitagliptin Metformin Extended Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Sitagliptin Metformin Extended Release Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Sitagliptin Metformin Extended Release Tablets Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Sitagliptin Metformin Extended Release Tablets Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Sitagliptin Phosphate 50mg (Calculated as C₁₆H₁₅F₆N₅O) and Metformin Hydrochloride 500mg
  • Sitagliptin Phosphate 100mg (Calculated as C16H15F6N5O) and Metformin Hydrochloride 1000mg
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Chia Tai Tianqing Pharmaceutical Group
  • Jiangsu Xuantai Pharmaceutical Co., Ltd.
  • Jiangsu Anbisheng Pharmaceutical Co., Ltd.
  • Sandoz Pty Ltd
  • Merck & Co., Inc.
  • Abbott

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032)
  4. 1.2.2 Global Sitagliptin Metformin Extended Release Tablets Sales Volume (2021-2032)
  5. 1.2.3 Global Sitagliptin Metformin Extended Release Tablets Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Sitagliptin Metformin Extended Release Tablets Market Dynamics
  1. 2.1 Sitagliptin Metformin Extended Release Tablets Industry Trends
  2. 2.2 Sitagliptin Metformin Extended Release Tablets Industry Drivers
  3. 2.3 Sitagliptin Metformin Extended Release Tablets Industry Opportunities and Challenges
  4. 2.4 Sitagliptin Metformin Extended Release Tablets Industry Restraints
3 Sitagliptin Metformin Extended Release Tablets Market by Company
  1. 3.1 Global Sitagliptin Metformin Extended Release Tablets Company Revenue Ranking in 2025
  2. 3.2 Global Sitagliptin Metformin Extended Release Tablets Revenue by Company (2021-2026)
  3. 3.3 Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Company (2021-2026)
  4. 3.4 Global Sitagliptin Metformin Extended Release Tablets Average Price by Company (2021-2026)
  5. 3.5 Global Sitagliptin Metformin Extended Release Tablets Company Ranking (2024-2026)
  6. 3.6 Global Sitagliptin Metformin Extended Release Tablets Company Manufacturing Base and Headquarters
  7. 3.7 Global Sitagliptin Metformin Extended Release Tablets Company Product Type and Application
  8. 3.8 Global Sitagliptin Metformin Extended Release Tablets Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Sitagliptin Metformin Extended Release Tablets Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Sitagliptin Metformin Extended Release Tablets Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Sitagliptin Metformin Extended Release Tablets Market by Type
  1. 4.1 Sitagliptin Metformin Extended Release Tablets Type Introduction
  2. 4.1.1 Sitagliptin Phosphate 50mg (Calculated as C₁₆H₁₅F₆N₅O) and Metformin Hydrochloride 500mg
  3. 4.1.2 Sitagliptin Phosphate 100mg (Calculated as C16H15F6N5O) and Metformin Hydrochloride 1000mg
  4. 4.2 Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Type
  5. 4.2.1 Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Type
  9. 4.3.1 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Type (2021-2032)
  11. 4.3.3 Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type (2021-2032)
5 Sitagliptin Metformin Extended Release Tablets Market by Application
  1. 5.1 Sitagliptin Metformin Extended Release Tablets Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Application
  6. 5.2.1 Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Sitagliptin Metformin Extended Release Tablets Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Sitagliptin Metformin Extended Release Tablets Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Application
  10. 5.3.1 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Application (2021-2032)
  12. 5.3.3 Global Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application (2021-2032)
6 Sitagliptin Metformin Extended Release Tablets Regional Sales and Value Analysis
  1. 6.1 Global Sitagliptin Metformin Extended Release Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Sitagliptin Metformin Extended Release Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Sitagliptin Metformin Extended Release Tablets Sales by Region: 2021-2026
  4. 6.2.2 Global Sitagliptin Metformin Extended Release Tablets Sales by Region (2027-2032)
  5. 6.3 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Region (2021-2032)
  7. 6.4.1 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Region: 2021-2026
  8. 6.4.2 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Region (2027-2032)
  9. 6.5 Global Sitagliptin Metformin Extended Release Tablets Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032)
  12. 6.6.2 North America Sitagliptin Metformin Extended Release Tablets Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032)
  15. 6.7.2 Europe Sitagliptin Metformin Extended Release Tablets Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Sitagliptin Metformin Extended Release Tablets Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032)
  21. 6.9.2 South America Sitagliptin Metformin Extended Release Tablets Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Sitagliptin Metformin Extended Release Tablets Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Sitagliptin Metformin Extended Release Tablets Sales Value Share by Country, 2025 VS 2032
7 Sitagliptin Metformin Extended Release Tablets Country-level Sales and Value Analysis
  1. 7.1 Global Sitagliptin Metformin Extended Release Tablets Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Sitagliptin Metformin Extended Release Tablets Sales by Country (2021-2032)
  4. 7.3.1 Global Sitagliptin Metformin Extended Release Tablets Sales by Country (2021-2026)
  5. 7.3.2 Global Sitagliptin Metformin Extended Release Tablets Sales by Country (2027-2032)
  6. 7.4 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Country (2021-2032)
  7. 7.4.1 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Country (2021-2026)
  8. 7.4.2 Global Sitagliptin Metformin Extended Release Tablets Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Sitagliptin Metformin Extended Release Tablets Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Sitagliptin Metformin Extended Release Tablets Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Sitagliptin Metformin Extended Release Tablets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chia Tai Tianqing Pharmaceutical Group
  2. 8.1.1 Chia Tai Tianqing Pharmaceutical Group Company Information
  3. 8.1.2 Chia Tai Tianqing Pharmaceutical Group Business Overview
  4. 8.1.3 Chia Tai Tianqing Pharmaceutical Group Sitagliptin Metformin Extended Release Tablets Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chia Tai Tianqing Pharmaceutical Group Sitagliptin Metformin Extended Release Tablets Product Portfolio
  6. 8.1.5 Chia Tai Tianqing Pharmaceutical Group Recent Developments
  7. 8.2 Jiangsu Xuantai Pharmaceutical Co., Ltd.
  8. 8.2.1 Jiangsu Xuantai Pharmaceutical Co., Ltd. Company Information
  9. 8.2.2 Jiangsu Xuantai Pharmaceutical Co., Ltd. Business Overview
  10. 8.2.3 Jiangsu Xuantai Pharmaceutical Co., Ltd. Sitagliptin Metformin Extended Release Tablets Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Jiangsu Xuantai Pharmaceutical Co., Ltd. Sitagliptin Metformin Extended Release Tablets Product Portfolio
  12. 8.2.5 Jiangsu Xuantai Pharmaceutical Co., Ltd. Recent Developments
  13. 8.3 Jiangsu Anbisheng Pharmaceutical Co., Ltd.
  14. 8.3.1 Jiangsu Anbisheng Pharmaceutical Co., Ltd. Company Information
  15. 8.3.2 Jiangsu Anbisheng Pharmaceutical Co., Ltd. Business Overview
  16. 8.3.3 Jiangsu Anbisheng Pharmaceutical Co., Ltd. Sitagliptin Metformin Extended Release Tablets Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Jiangsu Anbisheng Pharmaceutical Co., Ltd. Sitagliptin Metformin Extended Release Tablets Product Portfolio
  18. 8.3.5 Jiangsu Anbisheng Pharmaceutical Co., Ltd. Recent Developments
  19. 8.4 Sandoz Pty Ltd
  20. 8.4.1 Sandoz Pty Ltd Company Information
  21. 8.4.2 Sandoz Pty Ltd Business Overview
  22. 8.4.3 Sandoz Pty Ltd Sitagliptin Metformin Extended Release Tablets Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sandoz Pty Ltd Sitagliptin Metformin Extended Release Tablets Product Portfolio
  24. 8.4.5 Sandoz Pty Ltd Recent Developments
  25. 8.5 Merck & Co., Inc.
  26. 8.5.1 Merck & Co., Inc. Company Information
  27. 8.5.2 Merck & Co., Inc. Business Overview
  28. 8.5.3 Merck & Co., Inc. Sitagliptin Metformin Extended Release Tablets Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Merck & Co., Inc. Sitagliptin Metformin Extended Release Tablets Product Portfolio
  30. 8.5.5 Merck & Co., Inc. Recent Developments
  31. 8.6 Abbott
  32. 8.6.1 Abbott Company Information
  33. 8.6.2 Abbott Business Overview
  34. 8.6.3 Abbott Sitagliptin Metformin Extended Release Tablets Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Abbott Sitagliptin Metformin Extended Release Tablets Product Portfolio
  36. 8.6.5 Abbott Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Sitagliptin Metformin Extended Release Tablets Value Chain Analysis
  2. 9.1.1 Sitagliptin Metformin Extended Release Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Sitagliptin Metformin Extended Release Tablets Sales Mode & Process
  6. 9.2 Sitagliptin Metformin Extended Release Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Sitagliptin Metformin Extended Release Tablets Distributors
  9. 9.2.3 Sitagliptin Metformin Extended Release Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst